The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

1. PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials.Drugs · 2026
   Pooled it
2. Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management.BMC cardiovascular disorders · 2026
   Pooled it
3. Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells.Biology · 2026
   Article
4. PCSK9 in critical illness - It's not all about lipids.Annals of clinical biochemistry · 2026
   Review
5. Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.Research square · 2026
   Article
6. Cholesterol-modulating effects of Korean red ginseng (KRG) targeting PCSK9 in hyperlipidemia.Scientific reports · 2025
   Article
7. Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancers.Discover oncology · 2024
   Article
8. Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons.Endocrine · 2024
   Review
9. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.Signal transduction and targeted therapy · 2024
   Review
10. From target discovery to clinical drug development with human genetics.Nature · 2023
    Review
11. Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease.Pharmaceutics · 2023
    Review
12. Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis.Biomedicines · 2023
    Review
13. SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2.Viruses · 2023
    Article
14. Brazilin fromAdvances in pharmacological and pharmaceutical sciences · 2023
    Article
15. Low-Density Lipoprotein Receptor-Related Protein 8 at the Crossroad between Cancer and Neurodegeneration.International journal of molecular sciences · 2022
    Review
16. Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies.Journal of cardiovascular development and disease · 2022
    Review
17. Lowering low-density lipoprotein cholesterol: from mechanisms to therapies.Life metabolism · 2022
    Review
18. The Multifaceted Biology of PCSK9.Endocrine reviews · 2022
    Review
19. PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction.Life (Basel, Switzerland) · 2022
    Review
20. Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.Frontiers in oncology · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.